Advanced search
Publication Cover
Future Cardiology Volume 6, 2010 - Issue 3
Submit an article Journal homepage
109
Views
0
CrossRef citations to date
0
Altmetric
Review

Novel Neurohormonal Insights With Therapeutic Potential in Chronic Heart Failure

Jonathan R Dalzell1 Scottish Advanced Heart Failure Unit Golden Jubilee National HospitalGlasgowG81 4HXUK.Correspondence[email protected]
&
Colette E Jackson1 British Heart Foundation Cardiovascular Research Centre University of GlasgowGlasgowG12 8TAUK
Pages 361-372 | Published online: 12 May 2010

Bibliography

  • Mosterd A , HoesAW: Clinical epidemiology of heart failure.Heart, 93, 1137–1146 (2007).
  • Berry C , MurdochDR, McMurrayJJ: Economics of chronic heart failure.Eur. J. Heart Fail., 3, 283–291 (2001).
  • Stewart S , MacIntyreK, HoleDJ, CapewellS, McMurrayJJ: More ‘malignant‘ than cancer? Five-year survival following a first admission for heart failure.Eur. J. Heart Fail., 3, 315–322 (2001).
  • Jhund PS , MacintyreK, SimpsonCRet al.: Long-term trends in first hospitalization for heart failure and subsequent survival between 1986 and 2003: a population study of 5.1 million people.Circulation, 119, 515–523 (2009).
  • Tatemoto K , HosoyaM, HabataYet al.: Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor.Biochem. Biophys. Res. Commun., 251, 471–476 (1998).
  • O‘Dowd BF , HeiberM, ChanAet al.: A human gene that shows identity with the gene encoding the angiotensin receptor is located on chromosome 11.Gene, 136, 355–360 (1993).
  • Hosoya M , KawamataY, FukusumiSet al.: Molecular and functional characteristics of APJ. Tissue distribution of mRNA and interaction with the endogenous ligand apelin.J. Biol. Chem., 275, 21061–21067 (2000).
  • Vickers C , HalesP, KaushikVet al.: Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase.J. Biol. Chem., 277, 14838–14843 (2002).
  • Lee DK , SaldiviaVR, NguyenT, ChengR, GeorgeSR, O‘DowdBF: Modification of the terminal residue of apelin-13 antagonizes its hypotensive action.Endocrinology, 146(1), 231–236 (2005).
  • Kleinz MJ , DavenportAP: Immunocytochemical localization of the endogenous vasoactive peptide apelin to human vascular and endocardial endothelial cells.Regul. Pept., 118, 119–125 (2004).
  • Chen MM , AshleyEA, DengDXet al.: Novel role for the potent endogenous inotrope apelin in human cardiac dysfunction.Circulation, 108, 1432–1439 (2003).
  • Katagampola SD , MaguireJJ, MatthewsonSR, DavenportAP: 125I-(Pyr1) apelin-13 is a novel radioligand for localizing the APJ orphan receptor in human and rat tissues with evidence for a vasoconstrictor role in man.Brit. J. Pharmacol., 132, 1255–1260 (2001).
  • Kleinz MJ , SkepperJN, DavenportAP: Immunocytochemical localisation of the apelin receptor, APJ, to human cardiomyocytes, vascular smooth muscle and endothelial cells.Regul. Pept., 126, 233–240 (2005).
  • Kuba K , ZhangL, ImaiYet al.: Impaired heart contractility in apelin gene-deficient mice associated with aging and pressure overload.Circ. Res., 101, E32–E42 (2007).
  • Ashley EA , PowersJ, ChenMet al.: The endogenous peptide apelin potently improves cardiac contractility and reduces cardiac loading in vivo.Cardiovasc. Res., 65, 73–82 (2005).
  • De Mota N et al. , Reaux-Le Goazigo A, El Messari S : Apelin, a potent diuretic neuropeptide counteracting vasopressin actions through inhibition of vasopressin neuron activity and vasopressin release. Proc. Natl Acad. Sci. USA, 101, 10464–10469 (2004).
  • Hus-Citharel A , BoubyN, FrugièreA, BodineauL, GascJM, Llorens-CortesC: Effect of apelin on glomerular hemodynamic function in the rat kidney.Kidney Int., 74, 486–494 (2008).
  • Ernst KV , AshleyEA, CharoDet al.: Apelin regulates cardiac contractility and rescues neurohormonal heart failure (abstract).Circulation, 114, II 66 (2006).
  • Szokodi I , TaviP, FoldesGet al.: Apelin, the novel endogenous ligand of the orphan receptor APJ, regulates contractility.Circ. Res., 91, 434–400 (2002).
  • Farkasfalvi K , StaggMA, CoppenSRet al.: Direct effects of apelin on cardiomyocyte contractility and electrophysiology.Biochem. Biophys. Res. Comm., 357, 889–895 (2007).
  • Jia YX , PanCS, ZhangJet al.: Apelin protects myocardial injury induced by isoproterenol in rats.Regul. Pept., 133, 147–154 (2006).
  • Berry MF , PirolliTJ, JayasankarVet al.: Apelin has in vivo inotropic effects on normal and failing hearts.Circulation, 110, 187–193 (2004).
  • Iwanaga Y , KiharaY, TakenakaH, KitaT: Down-regulation of cardiac apelin system in hypertrophied and failing hearts:possible role of the angiotensin II-angiotensin type I receptor system.J. Mol. Cell Cardiol., 41, 798–806 (2006).
  • Fukushima H , KobayashiN, TakeshimaH, KoguchiW, IshimitsuT: Effects of olmesartan on apelin/APJ and Akt/eNOS pathway in Dahl rats with end-stage heart failure.J. Cardiovasc. Pharmacol., 55, 83–88 (2010).
  • Weir RA , ChongKS, DalzellJRet al.: Plasma apelin concentration is depressed following acute myocardial infarction in man.Eur. J. Heart Fail., 11, 551–558 (2009).
  • Maguire JJ , KleinzMJ, PitkinSL, DavenportAP: Pyr1apelin-13 identified as the predominant apelin isoform in the human heart: vasoactive mechanisms and inotropic action in disease.Hypertension, 54, 598–604 (2009).
  • Japp AG , CrudenNL, AmerDAet al.: Vascular effects of apelin in vivo in man.J. Am. Coll. Cardiol., 52, 908–913 (2008).
  • Chong KS , GardnerRS, MortonJJ, AshleyEA, McDonaghTA: Plasma concentrations of the novel peptide apelin are decreased in patients with chronic heart failure.Eur. J. Heart Fail., 8, 355–360 (2006).
  • Francia P , SalvatiA, BallaCet al.: Cardiac resynchronization therapy increases plasma levels of the endogenous inotrope apelin.Eur. J. Heart Fail., 9, 306–309 (2007).
  • Goetze JP , RehfeldJF, CarlsenJet al.: Apelin: a new plasma marker of cardiopulmonary disease.Regul. Pept., 133, 134–138 (2006).
  • Földes G , HorkayF, SzokodiIet al.: Circulating and cardiac levels of apelin, the novel ligand of the orphan receptor APJ, in patients with heart failure.Biochem. Biophys. Res. Commun., 308, 480–485 (2003).
  • Mullens W , BartunekJet al., Wilson Tang WH : Early and late effects of cardiac resynchronization therapy on force-frequency relation and contractility regulating gene expression in heart failure patients. Heart Rhythm, 5, 52–59 (2008).
  • Boonprasert P , LailerdN, ChattipakornN: Urocortins in heart failure and ischemic heart disease.Int. J. Cardiol., 127, 307–312 (2008).
  • Kimura Y , TakahashiK, TotsuneKet al.: Expression of urocortin and corticotropin-releasing factor receptor subtypes in the human heart.J. Clin. Endocrinol. Metab., 87, 340–346 (2002).
  • Hsu SY , HsuehAJ: Human stresscopin and stresscopin-related peptide are selective ligands for the type 2 corticotropin-releasing hormone receptor.Nat. Med., 7, 605–611 (2001).
  • Takahashi K , TotsuneK, MurakamiOet al.: Expression of urocortin III/stresscopin in human heart and kidney.J. Clin. Endocrinol. Metab., 89, 1897–1903 (2004).
  • Reyes TM , LewisK, PerrinMHet al.: Urocortin II: a member of the corticotropin-releasing factor (CRF) neuropeptide family that is selectively bound by type 2 CRF receptors.Proc. Natl Acad. Sci. USA, 98, 2843–2848 (2001).
  • Lewis K , LiC, PerrinMHet al.: Identification of urocortin III, an additional member of the corticotropin-releasing factor (CRF) family with high affinity for the CRF2 receptor.Proc. Natl Acad. Sci. USA, 98, 7570–7575 (2001).
  • Wiley KE , DavenportAP: CRF2 receptors are highly expressed in the human cardiovascular system and their cognate ligands urocortins 2 and 3 are potent vasodilators.Br. J. Pharmacol., 143, 508–514 (2004).
  • Parkes DG , VaughanJ, RivierJ, ValeW, MayCN: Cardiac inotropic actions of urocortin in conscious sheep.Am. J. Physiol., 272, H2115–H2122 (1997).
  • Terui K , HigashiyamaA, HoribaN, FurukawaKI, MotomuraS, SudaT: Coronary vasodilation and positive inotropism by urocortin in the isolated rat heart.J. Endocrinol., 169, 177–183 (2001).
  • Nishikimi T , MiyataA, HorioTet al.: Urocortin, a member of the corticotropin-releasing factor family, in normal and diseased heart.Am. J. Physiol. Heart Circ. Physiol., 279, H3031–H3039 (2000).
  • Ikeda K , TojoK, SatoSet al.: Urocortin, a newly identified corticotropin-releasing factor-related mammalian peptide, stimulates atrial natriuretic peptide and brain natriuretic peptide secretions from neonatal rat cardiomyocytes.Biochem. Biophys. Res. Commun., 250, 298–304 (1998).
  • Agnello D , BertiniR, SaccoS, MeazzaC, VillaP, GhezziP: Corticosteroid-independent inhibition of tumor necrosis factor production by the neuropeptide urocortin.Am. J. Physiol., 275, E757–E762 (1998).
  • Anker SD , von Haehling S: Inflammatory mediators in chronic heart failure: an overview. Heart, 90, 464–470 (2004).
  • Chen CY , DoongML, RivierJE, TachéY: Intravenous urocortin II decreases blood pressure through CRF(2) receptor in rats.Regul. Pept., 113, 125–130 (2003).
  • Mackay KB , StiefelTH, LingN, FosterAC: Effects of a selective agonist and antagonist of CRF2 receptors on cardiovascular function in the rat.Eur. J. Pharmacol., 469, 111–115 (2003).
  • Grossini E , MolinariC, MaryDA, MarinoP, VaccaG: The effect of urocortin II administration on the coronary circulation and cardiac function in the anaesthetized pig is nitric oxide-dependent.Eur. J. Pharmacol., 578, 242–248 (2008).
  • Coste SC , KestersonRA, HeldweinKA: Abnormal adaptations to stress and impaired cardiovascular function in mice lacking corticotropin-releasing hormone receptor-2.Nat. Genet., 24, 403–409 (2000).
  • Charles CJ , JardineDL, NichollsMG, RademakerMT, RichardsAM: Urocortin 1 exhibits potent inhibition of cardiac sympathetic nerve activity in conscious sheep.J. Hypertens., 26, 53–60 (2008).
  • Charles CJ , JardineDL, RademakerMT, RichardsAM: Urocortin 2 induces potent long-lasting inhibition of cardiac sympathetic drive despite baroreflex activation in conscious sheep.J. Endocrinol., 204, 181–189 (2010).
  • Rademaker MT , CharlesCJ, EspinerEA, FramptonCM, LainchburyJG, RichardsAM: Four-day urocortin-I administration has sustained beneficial haemodynamic, hormonal, and renal effects in experimental heart failure.Eur. Heart J., 26, 2055–2062 (2005).
  • Rademaker MT , CameronVA, CharlesCJ, RichardsAM: Integrated hemodynamic, hormonal, and renal actions of urocortin 2 in normal and paced sheep: beneficial effects in heart failure.Circulation, 112, 3624–3632 (2005).
  • Rademaker MT , CameronVA, CharlesCJ, RichardsAM: Urocortin 3: haemodynamic, hormonal, and renal effects in experimental heart failure.Eur. Heart J., 27, 2088–2098 (2006).
  • Bale TL , HoshijimaM, GuYet al.: The cardiovascular physiologic actions of urocortin II: acute effects in murine heart failure.Proc. Natl Acad. Sci. USA, 101, 3697–3702 (2004).
  • Rademaker MT , CharlesCJ, RichardsAM: Urocortin 1 administration from onset of rapid left ventricular pacing represses progression to overt heart failure.Am. J. Physiol. Heart Circ. Physiol., 293, H1536–H1544 (2007).
  • Rademaker MT , CharlesCJ, NichollsMG, RichardsAM: Urocortin 2 combined with angiotensin-converting enzyme inhibition in experimental heart failure.Clin. Sci. (Lond.), 114, 635–642 (2008).
  • Rademaker MT , CharlesCJ, NichollsMG, RichardsAM: Urocortin 2 inhibits furosemide-induced activation of renin and enhances renal function and diuretic responsiveness in experimental heart failure.Circ. Heart Fail., 2, 532–540 (2009).
  • Chen ZW , HuangY, YangQ, LiX, WeiW, HeGW: Urocortin-induced relaxation in the human internal mammary artery.Cardiovasc. Res., 65, 913–920 (2005).
  • Sanz E , MongeL, FernándezNet al.: Relaxation by urocortin of human saphenous veins.Br. J. Pharmacol., 136, 90–94 (2002).
  • Davis ME , PembertonCJ, YandleTGet al.: Urocortin-1 infusion in normal humans.J. Clin. Endocrinol. Metab., 89, 1402–1409 (2004).
  • Davis ME , PembertonCJ, YandleTGet al.: Urocortin 2 infusion in healthy humans: hemodynamic, neurohormonal, and renal responses.J. Am. Coll. Cardiol., 49, 461–471 (2007).
  • Ikeda K , TojoK, TokudomeGet al.: Cardiac expression of urocortin (Ucn) in diseased heart; preliminary results on possible involvement of Ucn in pathophysiology of cardiac diseases.Mol. Cell Biochem., 252, 25–32 (2003).
  • Wright SP , DoughtyRN, FramptonCM, GambleGD, YandleTG, RichardsAM: Plasma urocortin 1 in human heart failure.Circ. Heart Fail., 2, 465–471 (2009).
  • Davis ME , PembertonCJ, YandleTGet al.: Effect of urocortin 1 infusion in humans with stable congestive cardiac failure.Clin. Sci. (Lond)., 109, 381–388 (2005).
  • Davis ME , PembertonCJ, YandleTGet al.: Urocortin 2 infusion in human heart failure.Eur. Heart J., 28, 2589–2597 (2007).
  • Park JI , ChangCL, HsuSY: New insights into biological roles of relaxin and relaxin-related peptides.Rev. Endocr. Metab. Disord., 6, 291–296 (2005).
  • Kohsaka T , MinG, LukasG, TrupinS, CampbellET, SherwoodOD: Identification of specific relaxin-binding cells in the human female.Biol. Reprod., 59, 991–999 (1998).
  • Taylor MJ , ClarkCL: Evidence for a novel source of relaxin: atrial cardiocytes.J. Endocrinol., 143, R5–R8 (1994).
  • Hsu SY , NakabayashiK, NishiSet al.: Activation of orphan receptors by the hormone relaxin.Science, 295, 671–674 (2002).
  • Du XJ , SamuelCS, GaoXM, ZhaoL, ParryLJ, TregearGW: Increased myocardial collagen and ventricular diastolic dysfunction in relaxin deficient mice: a gender-specific phenotype.Cardiovasc. Res., 57, 395–404 (2003).
  • Kakouris H , EddieLW, SummersRJ: Cardiac effects of relaxin in rats.Lancet, 339, 1076–1078 (1992).
  • Toth M , TaskinenP, RuskoahoH: Relaxin stimulates atrial natriuretic peptide secretion in perfused rat heart.J. Endocrinol., 150, 487–495 (1996).
  • Bani-Sacchi T , BigazziM, BaniD, MannaioniPF, MasiniE: Relaxin-induced increased coronary flow through stimulation of nitric oxide production.Br. J. Pharmacol., 116, 1589–1594 (1995).
  • Danielson LA , SherwoodOD, ConradKP: Relaxin is a potent renal vasodilator in conscious rats.J. Clin. Invest., 103, 525–533 (1999).
  • Massicotte G , ParentA, St-LouisJ: Blunted responses to vasoconstrictors in mesenteric vasculature but not in portal vein of spontaneously hypertensive rats treated with relaxin.Proc. Soc. Exp. Biol. Med., 190, 254–259 (1989).
  • Dschietzig T , BartschC, RichterC, LauleM, BaumannG, StanglK: Relaxin, a pregnancy hormone, is a functional endothelin-1 antagonist: attenuation of endothelin-1-mediated vasoconstriction by stimulation of endothelin type-B receptor expression via ERK-1/2 and nuclear factor-κB.Circ. Res., 92, 32–40 (2003).
  • Debrah DO , ConradKP, DanielsonLA, ShroffSG: Effects of relaxin on systemic arterial hemodynamics and mechanical properties in conscious rats: sex dependency and dose response.J. Appl. Physiol., 98, 1013–1020 (2005).
  • Zhang J , QiYF, GengBet al.: Effect of relaxin on myocardial ischemia injury induced by isoproterenol.Peptides, 26, 1632–1639 (2005).
  • Bani D , NistriS, FormigliL, MeacciE, FranciniF, Zecchi-OrlandiniS: Prominent role of relaxin in improving postinfarction heart remodeling.Ann. NY Acad. Sci., 1160, 269–277 (2009).
  • Du XJ , XuQ, LekgabeEet al.: Reversal of cardiac fibrosis and related dysfunction by relaxin.Ann. NY Acad. Sci., 1160, 278–284 (2009).
  • Fisher C , MacLeanM, MorecroftIet al.: Is the pregnancy hormone relaxin also a vasodilator peptide secreted by the heart?Circulation, 106, 292–295 (2002).
  • Smith MC , DanielsonLA, ConradKP, DavisonJM: Influence of recombinant human relaxin on renal hemodynamics in healthy volunteers.J. Am. Soc. Nephrol., 17, 3192–3197 (2006).
  • Dschietzig T , RichterC, BartschCet al.: The pregnancy hormone relaxin is a player in human heart failure.FASEB J., 15, 2187–2195 (2001).
  • Fisher C , BerryC, BlueL, MortonJJ, McMurrayJ: N-terminal pro B type natriuretic peptide, but not the new putative cardiac hormone relaxin, predicts prognosis in patients with chronic heart failure.Heart, 89, 879–881 (2003).
  • Dschietzig T , TeichmanS, UnemoriEet al.: Intravenous recombinant human relaxin in compensated heart failure: a safety, tolerability, and pharmacodynamic trial.J. Card. Fail., 15, 182–190 (2009).
  • Teerlink JR , MetraM, FelkerGMet al.: Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding Phase IIb study.Lancet, 373, 1429–1439 (2009).
  • Nguyen G : Renin/prorenin receptors.Kidney Int., 69, 1503–1506 (2006).
  • Danser AH , DerkxFH, SchalekampMA, HenseHW, RieggerGA, SchunkertH: Determinants of inter individualvariation of renin and prorenin concentrations: evidence for a sexual dimorphism of (pro)renin levels in humans.J. Hypertens., 16, 853–862 (1998).
  • Deinum J , R⊘nnB, MathiesenE, DerkxFH, HopWC, SchalekampMA: Increase in serum prorenin precedes onset of microalbuminuria in patients with insulin-dependent diabetes mellitus.Diabetalogia, 42, 1006–1010 (1999).
  • Danser AH et al. , van den Dorpel MA, Deinum J : Renin, prorenin, and immunoreactive renin in vitreous fluid from eyes with and without diabetic retinopathy. J. Clin. Endocrinol. Metab., 68, 160–167 (1989).
  • Luetscher JA , KraemerFB, WilsonDM, SchwartzHC, Bryer-AshM: Increased plasma inactive renin in diabetes mellitus. A marker of microvascular complications.N. Engl. J. Med., 312, 1412–1417 (1985).
  • Danser AH et al. , van Kesteren CA, Bax WA : Prorenin, renin, angiotensinogen, and angiotensin-converting enzyme in normal and failing human hearts. Evidence for renin binding. Circulation, 96, 220–226 (1997).
  • Sealey JE , MoonC, LaraghJHet al.: Plasma prorenin in normal, hypertensive and anephric patients and its effect on renin measurements.Circ. Res., 40, 141–145 (1977).
  • Nguyen G , DelarueF, BurckleCet al.: Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin.J. Clin. Invest., 109, 1417–1427 (2002).
  • Batenburg WW , KropM, GarreldsIMet al.: Prorenin is the endogenous agonist of the (pro)renin receptor. Binding kinetics of renin and prorenin in rat vascular smooth muscle cells overexpressing the human (pro)renin receptor.J. Hypertens., 25, 2441–2453 (2007).
  • Burcklé CA et al. , Jan Danser AH, Müller DN : Elevated blood pressure and heart rate in human renin receptor transgenic rats. Hypertension, 47, 552–556 (2006).
  • Amsterdam A , NissenRM, SunZ, SwindellEC, FarringtonS, HopkinsN: Identification of 315 genes essential for early zebrafish development.Proc. Natl Acad. Sci. USA, 101, 12792–12797 (2004).
  • Ramser J , AbidiFE, BurckleCAet al.: A unique exonic splice enhancer mutation in a family with X-linked mental retardation and epilepsy points to a novel role of the renin receptor.Hum. Mol. Genet., 14, 019–027 (2005).
  • Hirose T , HashimotoM, TotsuneKet al.: Association of (pro)renin receptor gene polymorphism with blood pressure in Japanese men: the Ohasama study.Am. J. Hypertens., 22, 294–299 (2009).
  • Suzuki F , HayakawaM, NakagawaTet al.: Human prorenin has ‘gate and handle‘ regions for its non-proteolytic activation.J. Biol. Chem., 278, 22217–22222 (2003).
  • Huang Y , WongamornthamS, KastingJet al.: Renin increases mesangial cell transforming growth factor-β1 and matrix proteins through receptor-mediated, angiotensin II-independent mechanisms.Kidney Int., 69, 105–113 (2006).
  • Ichihara A , SuzukiF, NakagawaTet al.: Prorenin receptor blockade inhibits development of glomerulosclerosis in diabetic angiotensin II type 1a receptor-deficient mice.J. Am. Soc. Nephrol., 17, 1950–1961 (2006).
  • Huang Y , NobleNA, ZhangJ, XuC, BorderWA: Renin-stimulated TGF-β1 expression is regulated by a mitogen-activated protein kinase in mesangial cells.Kidney Int., 72, 45–52 (2007).
  • Saris JJ , HoenPA, GarreldsIMet al.: Prorenin induces intracellular signalling I cardiomyocytes independent of angiotensin II.Hypertension, 48, 564–571 (2006).
  • Sakoda M , IchiharaA, KaneshiroYet al.: (Pro)renin receptor-mediated activation of mitogen-activated protein kinases in human vascular smooth muscle cells.Hypertens. Res., 30, 1139–1146 (2007).
  • He M , ZhangL, ShaoYet al.: Inhibition of renin/prorenin receptor attenuated mesangial cell proliferation and reduced associated fibrotic factor release.Eur. J. Pharmacol., 606, 155–161 (2009).
  • Nabi AH , BiswasKB, NakagawaT, IchiharaA, InagamiT, SuzukiF: ‘Decoy peptide‘ region (RIFLKRMPSI) of prorenin prosegment plays a crucial role in prorenin binding to the (pro)renin receptor.Int. J. Mol. Med., 24, 83–89 (2009).
  • Ichihara A , HayashiM, KaneshiroYet al.: Inhibition of diabetic nephropathy by a decoy peptide corresponding to the ‘handle‘ region for nonproteolytic activation of prorenin.J. Clin. Invest., 114, 1128–1135 (2004).
  • Takahashi H , IchiharaA, KaneshiroYet al.: Regression of nephropathy developed in diabetes by (pro)renin receptor blockade.J. Am. Soc. Nephrol., 18, 2054–2061 (2007).
  • Ichihara A , KaneshiroY, TakemitsuTet al.: Nonproteolytic activation of prorenin contributes to development of cardiac fibrosis in genetic hypertension.Hypertension, 47, 894–900 (2006).
  • Satofuka S , IchiharaA, NagaiNet al.: Suppression of ocular inflammation in endotoxin-induced uveitis by inhibiting nonproteolytic activation of prorenin.Invest. Ophthalmol. Vis. Sci., 47, 2686–2692 (2006).
  • Feldt S , BatenburgWW, MazakIet al.: Prorenin and renin-induced extracellular signal-regulated kinase 1/2 activation in monocytes is not blocked by aliskiren or the handle-region peptide.Hypertension, 51, 682–688 (2008).
  • Feldt S , MaschkeU, DechendR, LuftFC, MullerDN: The putative (pro)renin receptor blocker HRP fails to prevent (pro)renin signaling.J. Am. Soc. Nephrol., 19, 743–748 (2008).
  • Packer M , MedinaN, YushakM, LeeWH: Usefulness of plasma renin activity in predicting haemodynamic and clinical responses and survival during long term converting enzyme inhibition in severe chronic heart failure. Experience in 100 consecutive patients.Br. Heart J., 54, 298–304 (1985).
  • McKenna F , DavisonAM: Renin and β-blockade: prorenin and aldosterone may explain the controversy.Clin. Nephrol., 25, 149–154 (1986).
  • Feldman DL , JinL, XuanHet al.: Effects of aliskiren on blood pressure, albuminuria, and (pro)renin receptor expression in diabetic TG(mRen-2)27 rats.Hypertension, 52, 130–136 (2008).
  • McMurray JJ , PittB, LatiniRet al.; for the Aliskiren Observation of Heart Failure Treatment (ALOFT) Investigators: Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ. Heart Fail., 1, 17–24 (2008).
  • Oparil S , YarowsSA, PatelS, FangH, ZhangJ, SatlinA: Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial.Lancet, 370, 221–229 (2007).
  • Donoghue M , HsiehF, BaronasEet al.: A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1–9.Circ. Res., 87, E1–E9 (2000).
  • Danilczyk U , PenningerJM: Angiotensin-converting enzyme II in the heart and the kidney.Circ. Res., 98, 463–471 (2006).
  • Lambert DW , YarskiM, WarnerFJet al.: Tumor necrosis factor-α convertase (ADAM17) mediates regulated ectodomain shedding of the severe-acute respiratory syndrome-coronavirus (SARS-CoV) receptor, angiotensin-converting enzyme-2 (ACE2).J. Biol. Chem., 280, 30113–30119 (2005).
  • Crackower MA , SaraoR, OuditGYet al.: Angiotensin-converting enzyme 2 is an essential regulator of heart function.Nature, 417, 822–828 (2002).
  • Nakamura K , KoibuchiN, NishimatsuHet al.: Candesartan ameliorates cardiac dysfunction observed in angiotensin-converting enzyme 2-deficient mice.Hypertens. Res., 31, 1953–1961 (2008).
  • Gurley SB , AllredA, LeTHet al.: Altered blood pressure responses and normal cardiac phenotype in ACE2-null mice.J. Clin. Invest., 116, 2218–2225 (2006).
  • Kassiri Z , ZhongJ, GuoDet al.: Loss of angiotensin-converting enzyme 2 accelerates maladaptive left ventricular remodeling in response to myocardial infarction.Circ. Heart Fail., 2, 446–455 (2009).
  • Yamamoto K , OhishiM, KatsuyaTet al.: Deletion of angiotensin-converting enzyme 2 accelerates pressure overload-induced cardiac dysfunction by increasing local angiotensin II.Hypertension, 47, 718–726 (2006).
  • Huentelman MJ , GrobeJL, VazquezJet al.: Protection from angiotensin II-induced cardiac hypertrophy and fibrosis by systemic lentiviral delivery of ACE2 in rats.Exp. Physiol., 90, 783–790 (2005).
  • Der Sarkissian S , GrobeJL, YuanLet al.: Cardiac overexpression of angiotensin converting enzyme 2 protects the heart from ischemia-induced pathophysiology.Hypertension, 51, 712–718 (2008).
  • Burrell LM , RisvanisJ, KubotaEet al.: Myocardial infarction increases ACE2 expression in rat and humans.Eur. Heart J., 26, 369–375 (2005).
  • Goulter AB , GoddardMJ, AllenJC, ClarkKL: ACE2 gene expression is up-regulated in the human failing heart.BMC Med., 2, 19 (2004).
  • Ferrario CM , JessupJ, ChappellMCet al.: Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2.Circulation, 111, 2605–2610 (2005).
  • Ishiyama Y , GallagherPE, AverillDB, TallantEA, BrosnihanKB, FerrarioCM: Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors.Hypertension, 43, 970–976 (2004).
  • Kaiqiang J i, Minakawa M, Fukui K, Suzuki Y, Fukuda I: Olmesartan improves left ventricular function in pressure-overload hypertrophied rat heart by blocking angiotensin II receptor with synergic effects of upregulation of angiotensin converting enzyme 2. Ther. Adv. Cardiovasc. Dis., 3, 103–111 (2009).
  • Epelman S , TangWH, ChenSY, Van Lente F, Francis GS, Sen S: Detection of soluble angiotensin-converting enzyme 2 in heart failure: insights into the endogenous counter-regulatory pathway of the renin-angiotensin-aldosterone system. J. Am. Coll. Cardiol., 52, 750–754 (2008).
  • Epelman S , ShresthaK, TroughtonRWet al.: Soluble angiotensin-converting enzyme 2 in human heart failure: relation with myocardial function and clinical outcomes.J. Card. Fail., 15, 565–571 (2009).
  • Fedak PW , MoravecCS, McCarthyPMet al.: Altered expression of disintegrin metalloproteinases and their inhibitor in human dilated cardiomyopathy.Circulation, 113, 238–245 (2006).
  • Wysocki J , YeM, RodriguezEet al.: Targeting the degradation of angiotensin II with recombinant angiotensin-converting enzyme 2: prevention of angiotensin II-dependent hypertension.Hypertension, 55, 90–98 (2010).
  • Santos RA , CastroCH, GavaEet al.: Impairment of in vitro and in vivo heart function in angiotensin-(1–7) receptor MAS knockout mice.Hypertension, 47, 996–1002 (2006).
  • Sampaio WO , NascimentoAA, SantosRA: Systemic and regional hemodynamic effects of angiotensin-(1–7) in rats.Am. J. Physiol. Heart Circ. Physiol., 284, H1985–H1994 (2003).
  • Averill DB , IshiyamaY, ChappellMC, FerrarioCM: Cardiac angiotensin-(1–7) in ischemic cardiomyopathy.Circulation, 108, 2141–2146 (2003).
  • Loot AE , RoksAJ, HenningRHet al.: Angiotensin-(1–7) attenuates the development of heart failure after myocardial infarction in rats.Circulation, 105, 1548–1550 (2002).
  • Ferreira AJ , JacobyBA, AraújoCAet al.: The nonpeptide angiotensin-(1–7) receptor Mas agonist AVE-0991 attenuates heart failure induced by myocardial infarction.Am. J. Physiol. Heart Circ. Physiol., 292, H1113–H1119 (2007).
  • Sasaki S , HigashiY, NakagawaK, MatsuuraH, KajiyamaG, OshimaT: Effects of angiotensin (1–7) on forearm circulation in normotensive subjects and patients with essential hypertension.Hypertension, 38, 90–94 (2001).
  • Roks AJ et al. , van Geel PP, Pinto YM : Angiotensin-(1–7) is a modulator of the human renin–angiotensin system. Hypertension, 34, 296–301 (1999).
  • Ueda S , Masumori-MaemotoS, AshinoKet al.: Angiotensin (1–7) attenuates vasoconstriction evoked by angiotensin II but not by noradrenaline in man.Hypertension, 35, 998–1001 (2000).
  • Luque M , MartinP, MartellN, FernandezC, BrosnihanKB, FerrarioCM: Effects of captopril related to increased levels of prostacyclin and angiotensin-(1–7) in essential hypertension.J. Hypertens., 14, 799–805 (1996).
  • Iyer SN , FerrarioCM, ChappellMC: Angiotensin-(1–7) contributes to the antihypertensive effects of blockade of the renin–angiotensin system.Hypertension, 31, 356–361 (1998).
  • Iyer SN , ChappellMC, AverillDB, DizDI, FerrarioCM: Vasodepressor actions of angiotensin-(1–7) unmasked during combined treatment with lisinopril and losartan.Hypertension, 31, 699–705 (1998).
  • Davie AP , McMurrayJJ: Effect of angiotensin-(1–7) and bradykinin in patients with heart failure treated with an ACE inhibitor.Hypertension, 34, 457–460 (1999).
  • Krum H , AbrahamWT: Heart failure.Lancet, 373, 941–955 (2009).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.